Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best fundamentally strong penny stocks to buy according to analysts. On December 19, TheFly reported that Cathie Wood’s ARK Investment has ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

What if the future of gaming wasn’t just about better graphics or faster processors, but about giving players the tools to shape their own experiences? Valve seems to think so. With the announcement ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. Yesterday, Valve announced ...

Valve has announced the Steam Frame, a standalone VR headset built to stream PC games with low latency and run Steam titles locally. It runs on a Snapdragon 8 Gen 3 chip and SteamOS. It is aimed at PC ...

What if a single device could redefine how you experience gaming, blending the immersive depth of virtual reality with the convenience of a portable console? Enter the Valve Steam Frame, a bold new ...

Valve has announced a next-gen virtual reality headset, dubbed Steam Frame. Steam Frame differs from its predecessor, Valve Index, in that it can be used as a standalone VR headset, and even comes ...

Want to know how Valve’s newly announced Steam Frame standalone headset stacks up against the competition? Read on to find out. Steam Frame is a lot like Steam Deck; it can play pretty much all of ...

Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...

Recursion Pharmaceuticals’s stock price closed at $5.00. It is down -6.72% in the last 3 months and down -28.26% in the last 12 months. Recursion Pharmaceuticals saw 0 positive EPS revisions and 4 ...